Google
OCUL — OCULAR THERAPEUTIX INC (Healthcare >> Biotechnology)
OCUL FAQ
What is OCUL's ROE?
OCULAR THERAPEUTIX INC reports a Return on Equity (ROE) of -49.95%.
What is OCUL's dividend yield?
OCULAR THERAPEUTIX INC offers a dividend yield of 0.00%.
What is OCUL's Deepscope Quality Score?
Deepscope rates OCUL's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OCUL?
Deepscope's AI Timing Score for OCUL is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OCUL belong to?
OCULAR THERAPEUTIX INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.74
Price
0.27
(3.19%)
Day Change
|
|
|---|
OCUL, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.74 |
| PBV / Sector |
3.19 / 4.79
|
| Earning Per Share | -1.37 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
21.09 M
GREAT
|
| Average 1W Daily Value |
16.13 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:54:33 |
| Symbol | OCUL |
| Name | OCULAR THERAPEUTIX INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 218.96 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,854.59 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 14 Crosby Drive, Bedford, MA, United States, 01730
Phone: 781 357 4000
Website: https://www.ocutx.com
Employees: 325
Sector: Healthcare >> Biotechnology
Description: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
